MarketCap
Facebook
X
TelegramQuarterly report 2024-Q4
added 01-10-2025
Accolade Balance Sheet 2011-2026 | ACCD
Annual Balance Sheet Accolade
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -12 M | -23.5 M | 7.34 M | - | - | - | - | - | - | - |
Long Term Debt |
- | 72.3 M | 19.2 M | 15.9 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 78.2 M | 240 M | 189 M | - | - | - | - | - | - | - |
Total Current Liabilities |
79.1 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
84.7 M | 148 M | 296 M | 231 M | - | - | - | - | - | - | - |
Deferred Revenue |
25.9 M | 33.6 M | 30.9 M | 14.8 M | - | - | - | - | - | - | - |
Retained Earnings |
-372 M | -321 M | -270 M | -213 M | - | - | - | - | - | - | - |
Total Assets |
476 M | 124 M | 65.8 M | 47.1 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
434 M | 33.2 M | 42.7 M | - | - | - | - | - | - | - | - |
Book Value |
391 M | -23.8 M | -231 M | -184 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
391 M | -257 M | -231 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Accolade
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
21.1 M | 22.6 M | 24.6 M | 26.1 M | 26.6 M | 24.2 M | 25.7 M | 27.2 M | 28.8 M | 30.7 M | 32.5 M | 32.5 M | - | - | - | - | - | - | 72.5 M | 21.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
334 M | 333 M | 332 M | 343 M | 351 M | 417 M | 422 M | 429 M | 428 M | 425 M | 410 M | 430 M | 475 M | 536 M | 454 M | 84.7 M | 79.2 M | 74.8 M | 154 M | 97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
38.3 M | 40.7 M | 38.7 M | 34.8 M | 52.8 M | 47.5 M | 44.2 M | 35.2 M | 43.5 M | 45 M | 36.9 M | 30.9 M | 43.1 M | 43.1 M | 32.9 M | 25.9 M | 34.4 M | 32.8 M | 34.4 M | 28.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.23 B | -1.11 B | -1.08 B | -1.05 B | -1.05 B | -1.03 B | -993 M | -954 M | -924 M | -884 M | -837 M | -495 M | -460 M | -483 M | -420 M | -372 M | -367 M | -350 M | -335 M | -321 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
647 M | 756 M | 767 M | 788 M | 785 M | 854 M | 876 M | 903 M | 914 M | 932 M | 944 M | 1.29 B | 1.26 B | 1.27 B | 891 M | 476 M | 467 M | 267 M | 120 M | 73.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
186 M | 173 M | 189 M | 186 M | 230 M | 292 M | 303 M | 321 M | 326 M | 331 M | 336 M | 366 M | 366 M | 384 M | 326 M | 434 M | 419 M | 222 M | 77.7 M | 33.2 M | 39.7 M | 23.9 M | 26.1 M | 42.7 M | - | - | - | 13.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
313 M | 423 M | 435 M | 445 M | 435 M | 438 M | 454 M | 474 M | 486 M | 506 M | 535 M | 856 M | 789 M | 734 M | 437 M | 391 M | 388 M | 192 M | -33.5 M | -23.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
313 M | 423 M | 435 M | 445 M | 435 M | 438 M | 454 M | 474 M | 486 M | 506 M | 535 M | 856 M | 789 M | 734 M | 437 M | 391 M | 388 M | 388 M | 192 M | -266 M | -264 M | -249 M | -245 M | -231 M | - | - | - | -184 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Accolade, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Evolent Health
EVH
|
$ 2.55 | 0.59 % | $ 239 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.22 | 3.02 % | $ 856 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
10x Genomics
TXG
|
$ 24.96 | 5.85 % | $ 2.92 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 6.01 | 1.26 % | $ 103 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.11 | 4.25 % | $ 77.6 M | USA |
 |
HealthEquity
HQY
|
$ 80.45 | 0.68 % | $ 6.93 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
$ 11.79 | 2.97 % | $ 866 M | USA |
 |
Phreesia
PHR
|
$ 8.59 | 0.35 % | $ 513 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Teladoc Health
TDOC
|
$ 5.24 | 0.29 % | $ 923 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
American Well Corporation
AMWL
|
$ 5.52 | -0.54 % | $ 88.6 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
HealthStream
HSTM
|
$ 20.35 | -0.1 % | $ 618 M | USA |
 |
Omnicell
OMCL
|
$ 36.24 | 3.51 % | $ 1.67 B | USA |
 |
Progyny
PGNY
|
$ 17.13 | 0.88 % | $ 1.47 B | USA |
 |
So-Young International
SY
|
$ 2.76 | 2.42 % | $ 219 M |  China |
 |
Veeva Systems
VEEV
|
$ 157.76 | -0.44 % | $ 25.8 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.99 | -1.24 % | $ 6.8 M | China |